Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × bintrafusp alfa protein, human × CNS × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡